课题基金 / 基金详情

Epigenetic regulation of neuropathic pain: Role of DRG histone methyltransferase G9a

Epigenetic regulation of neuropathic pain: Role of DRG histone methyltransferase G9a
神经性疼痛的表观遗传调控:DRG 组蛋白甲基转移酶 G9a 的作用
批准号:
9207019
负责人:
Yuan-Xiang Tao
金额:
$39.9万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-02-01 至 2021-01-31

项目摘要

项目成果

Yuan-Xiang Tao的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(申请人提供):目前对神经损伤引起的神经病理性疼痛的治疗是有限的,这是最常见的临床症状之一。了解与这种疾病相关的病理变化可能有助于将治疗策略从症状缓解转变为针对神经病理性疼痛的新疗法。周围神经损伤引起的背根节(DRG)受体、酶和电压依赖性离子通道表达的改变参与了神经病理性疼痛的发生。然而,神经损伤如何导致这些变化的分子机制仍然不清楚。最近的研究表明,基因调控的机制涉及表观遗传修饰,如组蛋白甲基化。组蛋白甲基转移酶G9a主要催化组蛋白H3赖氨酸9单甲基化(H3K9me1)和二甲基化(H3K9me2),是基因表达的关键调控因子。我们的初步数据表明,神经损伤诱导的DRG G9a增加可能是通过调控DRG u阿片受体(MOR)和kappa阿片受体(KOR)基因的表达而导致神经病理性疼痛的。这项提案将决定周围神经损伤后DRG G9a是否以及如何上调,以及G9a是否和如何在神经病理性疼痛条件下促进疼痛过敏。在目标1中,我们将确定在发育和维持期,DRG G9a的药物抑制或基因敲除是否可以减轻神经损伤引起的疼痛过敏,以及DRG G9a的过度表达是否会导致神经病理性疼痛的主要症状。目的2观察周围神经损伤后背根神经节中G9a、C/EBPβ的表达及H3K9me1、H3K9me2的表达。我们还将研究神经损伤诱导的DRGG9a表达上调是否归因于神经病理性疼痛条件下C/EBPβ与背根节中G9a基因启动子结合活性的增加。在目标3中,我们将研究G9a是否以及如何参与神经损伤诱导的背根节损伤后MOR和KOR的下调。我们将首先观察G9a是否与MOR和KOR基因的启动子和5‘端调控区结合,以及在第四次脊髓神经损伤(SNL)后,这些结合活性是否在受损的DRG神经元中增加。然后,我们将确定G9a是否通过阻止转录因子环AMP反应元件结合蛋白对这两个基因中的结合基序的访问,而参与SNL诱导的DRG、MOR和KOR的下调。最后,我们将确定阻断SNL诱导的DRG G9a增加是否拯救了受损DRG中MOR和KOR的下调,减少了初级传入神经递质的释放,恢复了阿片类止痛的减少,并减缓了阿片耐受的发展。这些研究不仅将促进我们对神经病理性疼痛的表观遗传学机制的理解,还将为开发预防和治疗这种疾病的新策略打开一扇门。
英文摘要
 DESCRIPTION (provided by applicant): Current treatment for nerve injury-induced neuropathic pain, one of the most common clinical syndromes, is limited. Understanding pathological changes related to this disorder may help shift treatment strategies from symptomatic relief to neuropathic pain-specific novel therapies. Peripheral nerve injury-induced changes in the expression of receptors, enzymes, and voltage-dependent ion channels in the dorsal root ganglion (DRG) contribute to neuropathic pain genesis. However, the molecular mechanisms of how nerve injury causes these changes are still elusive. Recent studies suggest that the mechanism for gene regulation involves epigenetic modification, such as histone methylation. G9a, a histone methyltransferase, primarily catalyzes histone H3 lysine 9 monomethylation (H3K9me1) and dimethylation (H3K9me2) and is a key regulator of gene expression. Our preliminary data indicate that a nerve injury-induced increase in DRG G9a may be responsible for neuropathic pain by governing the expression of DRG mu opioid receptor (MOR) and kappa opioid receptor (KOR) genes. This proposal will determine whether and how DRG G9a is up-regulated following peripheral nerve injury and whether and how G9a contributes to pain hypersensitivity under neuropathic pain conditions. In Aim 1, we will determine whether pharmacological inhibition or genetic knockdown of DRG G9a attenuates nerve injury-induced pain hypersensitivity during the development and maintenance periods and whether overexpression of DRG G9a leads to major symptoms of neuropathic pain. In Aim 2, we will observe the expression of G9a and C/EBPβ and the levels of H3K9me1 and H3K9me2 in the DRG after peripheral nerve injury. We will also examine whether nerve injury-induced up-regulation of DRG G9a is attributed to an increase in the binding activity of C/EBPβ to the G9a gene promoter in the DRG under neuropathic pain conditions. In Aim 3, we will examine whether and how G9a participates in the nerve injury- induced down-regulation of MOR and KOR in the injured DRG. We will first observe whether G9a binds to the promoter and 5'-end regulatory regions of MOR and KOR genes and whether these binding activities are increased in the injured DRG neurons after the fourth spinal nerve injury (SNL). We will then define whether G9a contributes to the SNL-induced down-regulation of DRG MOR and KOR by blocking the access of the transcriptional factor cyclic AMP response element binding protein to its binding motifs within these two genes. Finally, we will determine whether blocking the SNL-induced increase in DRG G9a rescues the downregulation of MOR and KOR in the injured DRG, reduces primary afferent neurotransmitter release, restores the decrease of opioid analgesia, and attenuates opioid tolerance development. These studies will not only advance our understanding of the epigenetic mechanisms of neuropathic pain but will also open a door to develop a new strategy for the prevention and treatment of this disorder.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of dorsal root ganglion FTO, a RNA demethylase, in neuropathic pain
Role of dorsal root ganglion FTO, a RNA demethylase, in neuropathic pain
  • 批准号:
    10175069
  • 项目类别:
  • 资助金额:
    $50.99万
  • 财政年份:
    2019
  • 负责人:
    Yuan-Xiang Tao
  • 依托单位:
Role of dorsal root ganglion FTO, a RNA demethylase, in neuropathic pain
Role of dorsal root ganglion FTO, a RNA demethylase, in neuropathic pain
  • 批准号:
    9978158
  • 项目类别:
  • 资助金额:
    $50.99万
  • 财政年份:
    2019
  • 负责人:
    Yuan-Xiang Tao
  • 依托单位:
国内基金
海外基金
Behavioral Insights on Cooperation in Social Dilemmas
  • 批准号:
    --
  • 项目类别:
    外国优秀青年学者研究基金项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    LIEN,Jaimie Wei-Hung
  • 依托单位: